



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 


PRODUCT INFORMATION



Stearic Acid glycidyl ester

Item No. 36838

CAS Registry No.: 7460-84-6
Formal Name: octadecanoic acid, 2-oxiranylmethyl ester
Synonyms: Glycidyl Octadecanoate, Glycidyl Stearate, NSC 404228, Octadecanoic Acid glycidyl ester
MF: C₂₁H₄₀O₃
FW: 340.5
Purity: ≥95%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Stearic acid glycidyl ester is supplied as a solid. A stock solution may be made by dissolving the stearic acid glycidyl ester in the solvent of choice, which should be purged with an inert gas. Stearic acid glycidyl ester is soluble in the organic solvent dimethyl formamide at a concentration of approximately 2 mg/ml.

Description

Stearic acid glycidyl ester is an esterified form of stearic acid (Item No. 10011298) containing a glycidyl group. It induces the formation of subcutaneous sarcomas and pulmonary tumors in mice when administered at doses ranging from 0.005-10 mg/animal and induces the formation of breast carcinomas in mice when administered at a dose of 0.1 mg/animal.¹ However, serum levels of stearic acid glycidyl ester are decreased in patients with prostate cancer compared to patients with benign prostatic hyperplasia and are negatively correlated with total cholesterol, LDL, and apolipoprotein B (ApoB) levels.²

References

1. Swern, D., Wieder, R., McDonough, M., *et al.* Investigation of fatty acids and derivatives for carcinogenic activity. *Cancer Res.* **30(4)**, 1037-1046 (1970).
2. Xu, B., Chen, Y., Chen, X., *et al.* Metabolomics profiling discriminates prostate cancer from benign prostatic hyperplasia within the prostate-specific antigen gray zone. *Front. Oncol.* **11**, 730638 (2021).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 12/21/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM